sur Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Announces Leadership Changes
Aspire Biopharma Holdings, Inc. has announced significant changes in its leadership. Kraig Higginson, who currently chairs the board, has been named interim CEO following the resignation of Michael C. Howe. Mr. Higginson has previously served as CEO for four years and will lead with the intent to maximize Aspire's drug delivery platform's potential. The board is initiating the search for a permanent CEO.
The company also announced the departure of board members Gary E. Stein and Barbara Sher. Howard Doss has been appointed Director and Chairman of the Audit Committee. Doss is a seasoned CFO with vast experience, having served in various financial roles, including at PowerUp and Kernel Group Holdings, Inc. He holds a degree from Illinois Wesleyan University and is affiliated with the American Institute of CPA's.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Aspire Biopharma, Inc.